SHANGHAI, 2 juillet 2023 /PRNewswire/ — Bioheart (02185.HK) et sa filiale Angiocare annoncent les résultats cliniques d’Iberis-HTN lors du salon China Interventional Therapeutics 2023. Iberis-HTN est un essai prospectif, multicentrique, randomisé, contrôlé et mené en aveugle, visant à…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.